Top

Breast Cancer Research and Treatment

Published in:

01-11-2003

E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide

Authors: Sehwan Han, Kyeongmee Park, Byung-Noe Bae, Ki Hwan Kim, Hong-Joo Kim, Young-Duck Kim, Hong-Yong Kim

Published in: Breast Cancer Research and Treatment | Issue 1/2003

Title: E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide
Authors: Sehwan Han
Kyeongmee Park
Byung-Noe Bae
Ki Hwan Kim
Hong-Joo Kim
Young-Duck Kim
Hong-Yong Kim
Publication date: 01-11-2003
Publisher: Kluwer Academic Publishers
Published in: Breast Cancer Research and Treatment / Issue 1/2003
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1023/B:BREA.0000003843.53726.63

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 1/2003

Familial Breast Cancer: Scope for More Susceptibility Genes?

Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer

Instructions for Authors

Predictive Factors for the Status of Non-sentinel Nodes in Breast Cancer Patients with Tumor Positive Sentinel Nodes

Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread

Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer